UK Chartered and European Patent Attorneys

Specialists in biotechnology, chemistry and pharmaceutical patents, we provide a full range of intellectual property services to our clients, who are based all over the world.

Established patent firm with exceptional pharmaceutical sector knowledge

Our client portfolio covers the spectrum of small businesses to industry leading FTSE 100 companies, including start-ups, academic research organisations, university spin-outs and venture capital funds. We have built our first-class reputation on the results we achieve for our clients and much of our new business comes through recommendations.

We have once again been ranked as one of Europe’s Leading Patent Law Firms by the Financial Times and Statista.

UK EU Referendum

On 31 January 2020 the United Kingdom (UK) entered the transition period for leaving the European Union (EU). Although a framework for the future relationship between the UK and EU remains to be determined, the European Patent Convention (EPC) is entirely independent from the EU. Therefore, the result of the referendum will not impact the UK’s membership of the EPC. As a UK-based firm of patent attorneys, Sagittarius IP will continue to be able to file European patent applications and we will continue to be able to handle clients’ present and future cases at the EPO. A granted European patent will continue to become a bundle of national patents in all validated states including the UK.

Community (EU) design rights are registered by the European Union Intellectual Property Office (EUIPO). Until the end of the transitional period on 31 December 2020, the UK’s relationship with the EU remains as before and all UK-based European design attorneys may still represent clients before the EUIPO in Community design matters. Therefore, Sagittarius IP will continue to be able to file Community design applications and we will continue to be able to handle clients’ cases at the EUIPO at least until the end of the transition period.